The early use of appropriate prophylactic antibiotics in susceptible women for the prevention of preterm birth of infectious etiology

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 15, 2014, Pages 2173-2191

  Joergensen, Jan Stener ^a   Kjær Weile, Louise Katrine ^a   Lamont, Ronald F ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Abnormal genital tract flora; Antibiotics; Bacterial vaginosis; Clindamycin; Metronidazole; Preterm birth; Prevention; Spontaneous preterm labor

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CLINDAMYCIN; ERYTHROMYCIN; METRONIDAZOLE; ANTIINFECTIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL LOAD; COST BENEFIT ANALYSIS; DRUG DOSE REGIMEN; DRUG USE; EARLY INTERVENTION; FIRST TRIMESTER PREGNANCY; GENOTYPE ENVIRONMENT INTERACTION; GESTATIONAL AGE; HIGH RISK POPULATION; HOST SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; INFANT MORTALITY; INFECTION SENSITIVITY; META ANALYSIS (TOPIC); NONHUMAN; PREMATURE LABOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESCREENING; REVIEW; SPONTANEOUS ABORTION; SPONTANEOUS PRETERM LABOR RESULTING IN PRETERM BIRTH; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; VAGINA FLORA; VAGINITIS; ABNORMAL GENITAL TRACT FLORA; BACTERIAL VAGINOSIS; FEMALE; MICROBIOLOGY; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PREMATURITY; PREVENTION; SPONTANEOUS PRETERM LABOR;

ABNORMAL GENITAL TRACT FLORA; ANTIBIOTICS; BACTERIAL VAGINOSIS; CLINDAMYCIN; METRONIDAZOLE; PRETERM BIRTH; PREVENTION; SPONTANEOUS PRETERM LABOR;

ANTI-BACTERIAL AGENTS; CLINDAMYCIN; FEMALE; HUMANS; INFANT, NEWBORN; METRONIDAZOLE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH;

EID: 84907276067     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.950225     Document Type: Review

References (148)

1. Romero R, Espinoza J, Mazor M, Chaiworapongsa T. The preterm parturition syndrome. In: Critchley H, Bennett P, Thornton S, editors, Preterm birth. First RCOG Press, London; 2004. p. 28-60
2. March of Dimes F. March of dimes white paper on Preterm birth: the global and regional toll. 2009. Available from: https:// marchofdimes.com/files/66423-MODComplete. pdf?src=mod.com [updated 16 December 2009]
3. Fellman V, Hellstrom-Westas L, Norman M, et al. One-year survival of extremely preterm infants after active perinatal care in Sweden. JAMA 2009;301(21):2225-33
4. Costeloe K, Hennessy E, Gibson AT, et al. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics 2000;106(4):659-71
5. Institute of Medicine. Preterm Birth: causes, consequences, and prevention. 2006. Available from: http://www. marchofdimes.com/prematurity/ index-about-10734.asp [updated 16 December 2009]
6. Petrou S, Abangma G, Johnson S, et al. Costs and health utilities associated with extremely preterm birth: evidence from the EPICure study. Value Health 2009;12(8):1124-34
7. Fidel P, Ghezzi F, Romero R, et al. The effect of antibiotic therapy on intrauterine infection-induced preterm parturition in rabbits. J Matern Fetal Neonatal Med 2003;14(1):57-64
8. Fidel PL Jr, Romero R, Wolf N, et al. Systemic and local cytokine profiles in endotoxin-induced preterm parturition in mice. Am J Obstet Gynecol 1994;170(5 Pt 1):1467-75
9. Gomez R, Ghezzi F, Romero R, et al. Premature labor and intra-amniotic infection. Clinical aspects and role of the cytokines in diagnosis and pathophysiology. Clin Perinatol 1995;22(2):281-342
10. Gomez R, Romero R, Mazor M, et al. Role of infection in preterm labor and delivery. In: Elder MG, Romero R, Lamont RF, editors. Preterm labor. Churchill Livingstone, New York; 1997. p. 85-125
11. Hirsch E, Wang H. The molecular pathophysiology of bacterially induced preterm labor: insights from the murine model. J Soc Gynecol Investig 2005;12(3):145-55
12. Romero R, Sepulveda W, Baumann P, et al. The preterm labor syndrome: biochemical, cytologic, immunologic, pathologic, microbiologic, and clinical evidence that preterm labor is a heterogeneous disease. Am J Obstet Gynecol 1993;168(1 part 2):287
13. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med 2000;342(20):1500-7
14. DiGiulio DB, Romero R, Amogan HP, et al. Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culturebased investigation. PLoS One 2008;3(8):e3056
15. Russell P. Inflammatory lesions of the human placenta. I. Clinical significance of acute chorioamnionitis. Am J Diagn Gynecol Obstet 1979;1(2):127-37
16. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991;29(2):297-301
17. Lamont RF, Sobel JD, Akins RA, et al. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG 2011;118(5):533-49
18. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005;353(18):1899-911
19. Srinivasan S, Hoffman NG, Morgan MT, et al. Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS One 2012;7(6):e37818
20. Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001-2004 national health and nutrition examination survey data. Obstet Gynecol 2007;109(1):114-20
21. Lamont RF. Bacterial vaginosis. In: Critchley H, Bennett P, Thornton S, editors. Preterm birth. RCOG Press, London; 2004. p. 163-80
22. Hay PE, Lamont RF, Taylor-Robinson D, et al. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ 1994;308(6924):295-8
23. Kurki T, Sivonen A, Renkonen OV, et al. Bacterial vaginosis in early pregnancy and pregnancy outcome. Obstet Gynecol 1992;80(2):173-7
24. Lamont RF, Nhan-Chang CL, Sobel JD, et al. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol 2011;205(3):177-90
25. Riduan JM, Hillier SL, Utomo B, et al. Bacterial vaginosis and prematurity in Indonesia: association in early and late pregnancy. Am J Obstet Gynecol 1993;169(1):175-8
26. McGregor JA, French JI, Jones W, et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream 1966. Am J Obstet Gynecol 1994;170(4):1048-59
27. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med 1995;333(26):1737-42
28. Meis PJ, Goldenberg RL, Mercer B, et al. The preterm prediction study: significance of vaginal infections. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1995;173(4):1231-5
29. Gravett MG, Nelson HP, DeRouen T, et al. Independent associations of bacterial vaginosis and Chlamydia trachomatis infection with adverse pregnancy outcome 1969. JAMA 1986;256(14):1899-903
30. Wennerholm UB, Holm B, Mattsby-Baltzer I, et al. Fetal fibronectin, endotoxin, bacterial vaginosis and cervical length as predictors of preterm birth and neonatal morbidity in twin pregnancies 1970. Br J Obstet Gynaecol 1997;104(12):1398-404
31. Gratacos E, Figueras F, Barranco M, et al. Spontaneous recovery of bacterial vaginosis during pregnancy is not associated with an improved perinatal outcome 1971. Acta Obstet Gynecol Scand 1998;77(1):37-40
32. Holst E, Goffeng AR, Andersch B. Bacterial vaginosis and vaginal microorganisms in idiopathic premature labor and association with pregnancy outcome 1972. J Clin Microbiol 1994;32(1):176-86
33. Eschenbach DA, Gravett MG, Chen KC, et al. Bacterial vaginosis during pregnancy. An association with prematurity and postpartum complications 1973. Scand J Urol Nephrol Suppl 1984;86:213-22
34. McDonald HM, O'Loughlin JA, Jolley P, et al. Prenatal microbiological risk factors associated with preterm birth. Br J Obstet Gynaecol 1992;99(3):190-6
35. Rosenstein IJ, Morgan DJ, Lamont RF, et al. Effect of intravaginal clindamycin cream on pregnancy outcome and on abnormal vaginal microbial flora of pregnant women. Infect Dis Obstet Gynecol 2000;8(3-4):158-65
36. Duff P, Lee ML, Hillier SL, et al. Amoxicillin treatment of bacterial vaginosis during pregnancy. Obstet Gynecol 1991;77(3):431-5
37. Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebocontrolled, double-blind study. Am J Obstet Gynecol 1994;171(2):345-7
38. Hauth JC, Goldenberg RL, Andrews WW, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995;333(26):1732-6
39. Joesoef MR, Hillier SL, Wiknjosastro G, et al. Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. Am J Obstet Gynecol 1995;173(5):1527-31
40. McGregor JA, French JI, Parker R, et al. Prevention of premature birth by screening and treatment for common genital tract infections: results of a prospective controlled evaluation. Am J Obstet Gynecol 1995;173(1):157-67
41. McDonald HM, O'Loughlin JA, Vigneswaran R, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial. Br J Obstet Gynaecol 1997;104(12):1391-7
42. Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebocontrolled double-blind trial. Br J Obstet Gynaecol 1999;106(7):652-7
43. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 2000;342(8):534-40
44. Kurkinen-Raty M, Vuopala S, Koskela M, et al. A randomised controlled trial of vaginal clindamycin for early pregnancy bacterial vaginosis. Br J Obstet Gynaecol 2000;107(11):1427-32
45. Kekki M, Kurki T, Pelkonen J, et al. Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial. Obstet Gynecol 2001;97(5 Pt 1):643-8
46. Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001;345(7):487-93
47. Porter K, Rambo D, Jazayeri M, Prien S. Prospective randomized trial of once versus twice a day metronidazole vaginal in obstetrical identified with bacterial vaginosis. Am J Obstet Gynecol 2001;184(1 Pt2):S166-S
48. Odendaal HJ, Popov I, Schoeman J, et al. Preterm labour - Is bacterial vaginosis involved? S Afr Med J 2002;92(3):231-4
49. Guaschino S, Ricci E, Franchi M, et al. Treatment of asymptomatic bacterial vaginosis to prevent pre-term delivery: a randomised trial. Eur J Obstet Gynecol Reprod Biol 2003;110(2):149-52
50. Lamont RF, Duncan SL, Mandal D, Bassett P. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol 2003;101(3):516-22
51. Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 2003;361(9362):983-8
52. Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ 2004;329(7462):371
53. Larsson PG, Fahraeus L, Carlsson B, et al. Late miscarriage and preterm birth after treatment with clindamycin: a randomised consent design study according to Zelen. BJOG 2006;113(6):629-37
54. McDonald HM, Brocklehurst P, Gordon A. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2007(1):CD000262
55. Swadpanich U, Lumbiganon P, Prasertcharoensook W, Laopaiboon M. Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database Syst Rev 2008(2):CD006178
56. Hutzal CE, Boyle EM, Kenyon SL, et al. Use of antibiotics for the treatment of preterm parturition and prevention of neonatal morbidity: a metaanalysis. Am J Obstet Gynecol 2008;199(6):620-8
57. Simcox R, Sin WT, Seed PT, et al. Prophylactic antibiotics for the prevention of preterm birth in women at risk: a meta-analysis. Aust NZ J Obstet Gynaecol 2007;47(5):368-77
58. Varma R, Gupta JK. Antibiotic treatment of bacterial vaginosis in pregnancy: multiple meta-analyses and dilemmas in interpretation. Eur J Obstet Gynecol Reprod Biol 2006;124(1):10-14
59. Okun N, Gronau KA, Hannah ME. Antibiotics for bacterial vaginosis or Trichomonas vaginalis in pregnancy: a systematic review. Obstet Gynecol 2005;105(4):857-68
60. Riggs MA, Klebanoff MA. Treatment of vaginal infections to prevent preterm birth: a meta-analysis. Clin Obstet Gynecol 2004;47(4):796-807
61. Leitich H, Brunbauer M, Bodner-Adler B, et al. Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis. Am J Obstet Gynecol 2003;188(3):752-8
62. Koumans EH, Markowitz LE, Hogan V. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis 2002;35(Suppl 2):S152-S72
63. Guise JM, Mahon SM, Aickin M, et al. Screening for bacterial vaginosis in pregnancy. Am J Prev Med 2001;20(3 Suppl):62-72
64. Klein LL, Gibbs RS. Use of microbial cultures and antibiotics in the prevention of infection-associated preterm birth. Am J Obstet Gynecol 2004;190(6):1493-502
65. Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2013;1:Cd000262
66. Lamont RF, Khan KS, Beattie B, et al. The quality of nifedipine studies used to assess tocolytic efficacy: a systematic review. J Perinat Med 2005;33(4):287-95
67. Hay PE, Taylor-Robinson D, Lamont RF. Preterm premature rupture of membranes. Lancet 1996;347(8995):203
68. Lamont RF. Infection and preterm labour. Br J Obstet Gynaecol 1998;105(12):1339-40
69. Lamont RF. Antibiotics for the prevention of preterm birth. N Engl J Med 2000;342(8):581-3
70. Lamont RF, Taylor-Robinson D, Hay PE. Antibiotics for adverse outcomes of pregnancy. Lancet 2001;358(9294):1728-9
71. Lamont RF. Antibiotics used in women at risk of preterm birth. Am J Obstet Gynecol 2008;199(6):583-4
72. Lamont RF. Association between cerebral palsy and erythromycin. Lancet 2009;373(9657):26
73. Mason MR, Adrinkra PE, Lamont RF. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased risk: a randomised placebo-controlled doubleblind trial. BJOG 2000;107(2):295-6
74. Lamont RF. The maternal fetal medicine network trial. Am J Obstet Gynecol 2005;193(1):306-7
75. Lamont RF. Preterm labour prevention clinics. BJOG 2014; In Press 76. Lamont RF. Changes in vaginal flora after 2% clindamycin vaginal cream in women at high risk of preterm birth. BJOG 2003;110:788-9
76. Kenyon S, Pike K, Jones DR, et al. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet 2008;372(9646):1319-27
77. Kenyon SL, Taylor DJ, Tarnow-Mordi W. Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group. Lancet 2001;357(9261):989-94
78. Gravett MG, Witkin SS, Haluska GJ, et al. An experimental model for intraamniotic infection and preterm labor in rhesus monkeys. Am J Obstet Gynecol 1994;171(6):1660-7
79. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR 2006;55(RR-11):1-94
80. Cassell GH, Crouse DT, Waites KB, et al. Does Ureaplasma urealyticum cause respiratory disease in newborns? Pediatr Infect Dis J 1988;7(8):535-41
81. Taylor-Robinson D, Morgan DJ, Sheehan M, et al. Relation between Gram-stain and clinical criteria for diagnosing bacterial vaginosis with special reference to Gram grade II evaluation. Int J STD AIDS 2003;14(1):6-10
82. Lamont RF, Taylor-Robinson D, Bassett P. Rescreening for abnormal vaginal flora in pregnancy and re-treating with clindamycin vaginal cream significantly increases cure and improvement rates. Int J STD AIDS 2012;23(8):565-9
83. Alfirevic A, Alfirevic Z, Pirmohamed M. Pharmacogenetics in reproductive and perinatal medicine. Pharmacogenomics 2010;11(1):65-79
84. Finnstrom O, Olausson PO, Sedin G, et al. The Swedish national prospective study on extremely low birthweight (ELBW) infants. Incidence, mortality, morbidity and survival in relation to level of care. Acta Paediatr 1997;86(5):503-11
85. Macones GA, Parry S, Elkousy M, et al. A polymorphism in the promoter region of TNF and bacterial vaginosis: preliminary evidence of gene-environment interaction in the etiology of spontaneous preterm birth. Am J Obstet Gynecol 2004;190(6):1504-8; discussion 3A
86. Bakketeig LS, Hoffman HJ, Harley EE. The tendency to repeat gestational age and birth weight in successive births. Am J Obstet Gynecol 1979;135(8):1086-103
87. Hoffman HJ, Bakketeig LS. Risk factors associated with the occurrence of preterm birth. Clin Obstet Gynecol 1984;27(3):539-52
88. Shennan A, Crawshaw S, Briley A, et al. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study. BJOG 2006;113(1):65-74
89. Lamont RF, Dragovic B. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study by Shennan et al. BJOG 2006;113(7):850-1
90. Aagaard K, Ma J, Antony KM, et al. The placenta harbors a unique microbiome. Sci Transl Med 2014;6(237):237ra65
91. Sanu O, Lamont RF. Periodontal disease and bacterial vaginosis as genetic and environmental markers for the risk of spontaneous preterm labor and preterm birth. J Matern Fetal Neonatal Med 2011;24(12):1476-85
92. Pretorius C, Jagatt A, Lamont RF. The relationship between periodontal disease, bacterial vaginosis, and preterm birth. J Perinat Med 2007;35(2):93-9
93. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 1978;70(1):51-5
94. Hand WL, Hand DL, King-Thompson NL. Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1990;34(5):863-70
95. Konno S, Asano K, Kurokawa M, et al. Antiasthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo. Int Arch Allergy Immunol 1994;105(3):308-16
96. Mikasa K, Kita E, Sawaki M, et al. The anti-inflammatory effect of erythromycin in zymosan-induced peritonitis of mice. J Antimicrob Chemother 1992;30(3):339-48
97. Takeshita K, Yamagishi I, Harada M, et al. Immunological and antiinflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs Exp Clin Res 1989;15(11-12):527-33
98. Barry AL, Thornsberry C, Jones RN. In vitro activity of a new macrolide, A- 56268, compared with that of roxithromycin, erythromycin, and clindamycin. Antimicrob Agents Chemother 1987;31(2):343-5
99. Young RA, Gonzalez JP, Sorkin EM. Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1989;37(1):8-41
100. Hillier SL, Holmes KK. Bacterial vaginosis. In: Holmes KK, Markowitz LE, Spellacy W, Wiggins R, editors. Sexually transmitted diseases. 2nd edition. McGraw-Hill; New York: 1990. p. 547-50
101. Spiegel CA, Eschenbach DA, Amsel R, Holmes KK. Curved anaerobic bacteria in bacterial (nonspecific) vaginosis and their response to antimicrobial therapy. J Infect Dis 1983;148(5):817-22
102. Spiegel CA. Susceptibility of Mobiluncus species to 23 antimicrobial agents and 15 other compounds. Antimicrob Agents Chemother 1987;31(2):249-52
103. Lamont RF, Jones BM, Mandal D, et al. The efficacy of vaginal clindamycin for the treatment of abnormal genital tract flora in pregnancy. Infect Dis Obstet Gynecol 2003;11(4):181-9
104. McDonald HM, O'Loughlin JA, Vigneswaran R, et al. Bacterial vaginosis in pregnancy and efficacy of short-course oral metronidazole treatment: a randomized controlled trial. Obstet Gynecol 1994;84(3):343-8
105. Ugwumadu A, Reid F, Hay P, Manyonda I. Natural history of bacterial vaginosis and intermediate flora in pregnancy and effect of oral clindamycin. Obstet Gynecol 2004;104(1):114-19
106. Vermeulen GM, van Zwet AA, Bruinse HW. Changes in the vaginal flora after two percent clindamycin vaginal cream in women at high risk of spontaneous preterm birth. BJOG 2001;108(7):697-700
107. Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis. Antimicrob Agents Chemother 2002;46(12):3995-6
108. Xiao JC, Xie LF, Fang SL, et al. Symbiosis of Mycoplasma hominis in Trichomonas vaginalis may link metronidazole resistance in vitro. Parasitol Res 2006;100(1):123-30
109. De Backer E, Dubreuil L, Brauman M, et al. In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis. Clin Microbiol Infect 2010;16(5):470-2
110. . Jr Ferris MJ, Masztal A, Aldridge KE, et al. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis 2004;4:5
111. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006;193(11):1478-86
112. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR 2010;59(RR-12):1-110
113. Amann U, Egen-Lappe V, Strunz-Lehner C, Hasford J. Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund population. Pharmacoepidemiol Drug Saf 2006;15(5):327-37
114. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol 2008;3:563-78
115. Borin MT, Powley GW, Tackwell KR, Batts DH. Absorption of clindamycin after intravaginal application of clindamycin phosphate 2% cream. J Antimicrob Chemother 1995;35(6):833-41
116. Moniri RBM. Effects of metronidazole therapy on preterm labor in women with bacterial vaginosis. Acta Med Iran 2009;47(3):181-4
117. Viniker DA. Hypothesis on the role of sub-clinical bacteria of the endometrium (bacteria endometrialis) in gynaecological and obstetric enigmas. Hum Reprod Update 1999;5(4):373-85
118. Goplerud CP, Ohm MJ, Galask RP. Aerobic and anaerobic flora of the cervix during pregnancy and the puerperium. Am J Obstet Gynecol 1976;126(7):858-68
119. Goldenberg RL, Rouse DJ. Prevention of premature birth. N Engl J Med 1998;339(5):313-20
120. Seo K, McGregor JA, French JI. Preterm birth is associated with increased risk of maternal and neonatal infection. Obstet Gynecol 1992;79(1):75-80
121. Shim SS, Romero R, Hong JS, et al. Clinical significance of intra-amniotic inflammation in patients with preterm premature rupture of membranes. Am J Obstet Gynecol 2004;191(4):1339-45
122. Kurki T, Sivonen A, Renkonen OV, et al. Bacterial vaginosis in early pregnancy and pregnancy outcome. Obstet Gynecol 1992;80(2):173-7
123. Berg TG, Philpot KL, Welsh MS, et al. Ureaplasma/Mycoplasma-infected amniotic fluid: pregnancy outcome in treated and nontreated patients. J Perinatol 1999;19(4):275-7
124. Cassell GH, Davis RO, Waites KB, et al. Isolation of Mycoplasma hominis and Ureaplasma urealyticum from amniotic fluid at 16-20 weeks of gestation: potential effect on outcome of pregnancy. Sex Transm Dis 1983;10(4 Suppl):294-302
125. Gerber S, Vial Y, Hohlfeld P, Witkin SS. Detection of Ureaplasma urealyticum in second-trimester amniotic fluid by polymerase chain reaction correlates with subsequent preterm labor and delivery. J Infect Dis 2003;187(3):518-21
126. Gray DJ, Robinson HB, Malone J, Thomson RB. Jr. Adverse outcome in pregnancy following amniotic fluid isolation of Ureaplasma urealyticum. Prenat Diagn 1992;12(2):111-17
127. Horowitz S, Mazor M, Romero R, et al. Infection of the amniotic cavity with Ureaplasma urealyticum in the midtrimester of pregnancy. J Reprod Med 1995;40(5):375-9
128. Nguyen DP, Gerber S, Hohlfeld P, et al. Mycoplasma hominis in mid-trimester amniotic fluid: relation to pregnancy outcome. J Perinat Med 2004;32(4):323-6
129. Perni SC, Vardhana S, Korneeva I, et al. Mycoplasma hominis and Ureaplasma urealyticum in midtrimester amniotic fluid: association with amniotic fluid cytokine levels and pregnancy outcome. Am J Obstet Gynecol 2004;191(4):1382-6
130. Screening for bacterial vaginosis in pregnancy to prevent preterm delivery: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;148(3):214-19
131. Nygren P, Fu R, Freeman M, et al. Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the U.S. Preventive Services Task Force. Ann Intern Med 2008;148(3):220-33
132. Koumans EH, Workowski KA, Ugwumadu A. Were inclusion criteria for the USPSTF review on BV treatment during pregnancy consistently applied? 2009. Available from: http://annals.org/ content/148/3/214.abstract/reply - Annintmed-el-115388 [Updated 05 April 2010
133. Morgan DJ, Taylor-Robinson D. Late miscarriage and preterm birth after treatment with clindamycin: a randomised consent design study according to Zelen. BJOG 2006;113(12):1483
134. Ingemarsson I. Tocolytic therapy and clinical experience. Combination therapy. BJOG 2005;112(Suppl 1):89-93
135. Broe A, Pottegard A, Lamont R, et al. Increasing use of antibiotics in pregnancy during the period 2000-2010: prevalence, timing, category, and demographics. BJOG 2014;121(8):988-96
136. Lamont HF BH, Lamont RF. Safety of Antimicrobial Treatment During Pregnancy: a Current Review of Resistance, Immunomodulation and Teratogenicity. Expert Opin Drug Saf 2014; In Press
137. Thomas M, Price D. Prenatal antibiotic exposure and subsequent atopy. Am J Respir Crit Care Med 2003;167(11):1578; author reply -9
138. McKeever TM, Lewis SA, Smith C, Hubbard R. The importance of prenatal exposures on the development of allergic disease: a birth cohort study using theWest Midlands General Practice Database. Am J Respir Crit Care Med 2002;166(6):827-32
139. Tsakok T, McKeever TM, Yeo L, Flohr C. Does early life exposure to antibiotics increase the risk of eczema? A systematic review. Br J Dermatol 2013;169(5):983-91
140. Stensballe LG, Simonsen J, Jensen SM, et al. Use of antibiotics during pregnancy increases the risk of asthma in early childhood. J Pediatr 2013;162(4):832-8.e3
141. Bisgaard H, Hermansen MN, Buchvald F, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med 2007;357(15):1487-95
142. Lamont RF. Setting up a preterm prevention clinic: a practical guide. BJOG 2006;113(Suppl 3):86-92
143. Sharp AN, Alfirevic Z. Provision and practice of specialist preterm labour clinics: a UK survey of practice. BJOG 2014;121(4):417-21
144. Lamont RF. Preterm labour prevention clinics. BJOG 2014;In Press
145. Jørgensen J S WLK, Lamont R F. Preterm prevention clinics. BJOG 2014;In Press
146. Romero R, Hassan SS, Gajer P, et al. The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women. Microbiome 2014;2(1):4
147. Hoyme UB, Saling E. Efficient prematurity prevention is possible by pH-self measurement and immediate therapy of threatening ascending infection. Eur J Obstet Gynecol Reprod Biol 2004;115(2):148-53
148. Niebyl JR. Antibiotics and other antiinfective agents in pregnancy and lactation. Am J Perinatol 2003;20(8):405-14